The emphasis of genetics over morphology is particularly notable in the ICC classification of TP53-mutated myeloid neoplasms, which are now grouped together and set apart from other MDS and AML subtypes in order to convey the uniquely aggressive nature of these diseases, regardless of the blast percentage or presence of dysplasia. This evidence concerns the gene TP53 and myelodysplastic syndrome.